About IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited (IOLCP) was established in 1986 and is listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164). The company is a leading manufacturer of pharmaceutical active pharmaceutical ingredients (APIs) and a significant player in specialty chemicals, supported by world-class facilities and backward integration in key products. Its portfolio spans major therapeutic areas such as pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets, with APIs including Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine and Pantoprazole, and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

IOLCP is the world’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA, and operates a DSIR-approved R&D centre to validate and improve processes. Its infrastructure includes an Effluent Treatment Plant (ETP) with a Zero Liquid Discharge (ZLD) system and a 17 MW captive co-generation plant, and the company holds ISO 9001:2015, ISO 14001:2015 and BS OHSAS 18001:2007 certifications.

The company serves branded generic formulators in India and overseas, with a broad international footprint. Key markets include the UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, the USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea and Thailand, among others.

IOL Chemicals and Pharmaceuticals Limited Key milestones include:

• Establishment and stock exchange listings (NSE and BSE).

• Emergence as the world’s largest Ibuprofen producer (12,000 TPA) with backward integration.

• Commissioning of DSIR-approved R&D, ETP with ZLD, and a 17 MW captive co-generation plant; attainment of ISO certifications.

IOL Chemicals and Pharmaceuticals Limited’s Key Management

• Dr Sanjay Chaturvedi – Chief Executive Officer.

Latest Updates on IOL Chemicals and Pharmaceuticals Limited

In the quarter ended June 30, 2021, IOLCP reported total income of Rs 524 crore, EBITDA of Rs 116 crore, profit before tax of Rs 90 crore and profit after tax of Rs 67 crore. On a quarter-on-quarter basis, total income grew 12%, while EBITDA was broadly flat; year-on-year, EBITDA declined due to stressed demand amid the second wave of Covid-19 globally.

Operational developments and highlights:

The chemicals segment performed strongly during the quarter in both revenue and profit terms.

Completion of “Unit-10”, a new manufacturing facility to produce multiple APIs including Fenofibrate, Lamotrigine and Ursodeoxycholic Acid (UDCA), to meet growing demand.

“Unit-9”, a new facility for Gabapentin and other APIs, experienced a schedule shift due to the second wave, with completion expected in the third quarter of FY22 without cost overrun.

Products and Services at a Glance

• APIs: Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole.

• Specialty chemicals: Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid, Acetyl Chloride.

• Capabilities and systems: DSIR-approved R&D; ETP with ZLD; 17 MW captive co-generation; ISO 9001:2015, ISO 14001:2015 and BS OHSAS 18001:2007.

Geographies Covered

• India and key international markets across Europe, North America, South America and Asia-Pacific, including the UK, Germany, Italy, USA, Australia, Brazil, Mexico, Indonesia, South Korea and Thailand, among others.